BackgroundRegulates activation of NF-kappa-B and JNK and plays a central role in the regulation of cell survival and apoptosis. Required for normal antibody isotype switching from IgM to IgG. Has E3 ubiquitin-protein ligase activity and promotes 'Lys-63'-linked ubiquitination of target proteins, such as BIRC3, RIPK1 and TICAM1. Is an essential constituent of several E3 ubiquitin-protein ligase complexes, where it promotes the ubiquitination of target proteins by bringing them into contact with other E3 ubiquitin ligases. Regulates BIRC2 and BIRC3 protein levels by inhibiting their autoubiquitination and subsequent degradation; this does not depend on the TRAF2 RING-type zinc finger domain. Plays a role in mediating activation of NF-kappa-B by EIF2AK2/PKR. In complex with BIRC2 or BIRC3, promotes ubiquitination of IKBKE.
DescriptionTRAF2 Recombinant Monoclonal Antibody [9A5]. Unconjugated. Raised in: HEK293F Cell.
FormulationBuffer: Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
SpecificityHuman
IsotypeRabbit IgG
Uniprot IDQ12933
PurificationAffinity Chromatography
ImmunogenA synthesized peptide derived from human TRAF2
StorageUpon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Alternative NamesTNF receptor-associated factor 2 (EC 2.3.2.27) (E3 ubiquitin-protein ligase TRAF2) (RING-type E3 ubiquitin transferase TRAF2) (Tumor necrosis factor type 2 receptor-associated protein 3), TRAF2, TRAP3
ApplicationELISA, WB, IHC, FC, IP; Recommended dilution: WB:1:500-1:5000, IHC:1:50-1:200, FC:1:20-1:200, IP:1:200-1:1000